Advances in the development of biomarkers for epilepsy.

@article{Pitknen2016AdvancesIT,
  title={Advances in the development of biomarkers for epilepsy.},
  author={Asla Pitk{\"a}nen and Wolfgang L{\"o}scher and Annamaria Vezzani and Albert J. Becker and Michele Simonato and Katarzyna Lukasiuk and Olli Gr{\"o}hn and Jens P. Bankstahl and Alon Friedman and E. Aronica and Jan A. Gorter and Teresa Ravizza and Sanjay M. Sisodiya and Merab Kokaia and Heinz Beck},
  journal={The Lancet. Neurology},
  year={2016},
  volume={15 8},
  pages={
          843-856
        }
}
Over 50 million people worldwide have epilepsy. In nearly 30% of these cases, epilepsy remains unsatisfactorily controlled despite the availability of over 20 antiepileptic drugs. Moreover, no treatments exist to prevent the development of epilepsy in those at risk, despite an increasing understanding of the underlying molecular and cellular pathways. One of the major factors that have impeded rapid progress in these areas is the complex and multifactorial nature of epilepsy, and its… CONTINUE READING
Related Discussions
This paper has been referenced on Twitter 14 times. VIEW TWEETS

From This Paper

Topics from this paper.

Citations

Publications citing this paper.
Showing 1-10 of 22 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 107 references

Similar Papers

Loading similar papers…